If mesoblast history is anything to go by, I have a feeling that this week we will receive FDA/OTAT minutes advising that mesoblast is on the right track but needs to refine a few further issues with potency/manufacturing and another meeting will be held in 4-6 months time once this issue is sorted. I am hoping that by posting this, this won’t happen, but I don’t want my expectations let down yet again
Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics, page-272
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.17 | $1.13 | $3.743M | 3.261M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78561 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 114667 | 4 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |